⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL329744 | 0.70 | — | — | |
| SCHEMBL10545264 | 0.59 | — | — | |
| SCHEMBL8758 | 0.56 | — | — | |
| SCHEMBL329462 | 0.56 | — | — | |
| SCHEMBL3959559 | 0.56 | — | — | |
| SCHEMBL1445441 | 0.56 | — | — | |
| SCHEMBL5074259 | 0.56 | — | — | |
| SCHEMBL2351501 | 0.56 | — | — | |
| SCHEMBL10021402 | 0.56 | — | — | |
| SCHEMBL329489 | 0.56 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 219 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115785014-B | Tetrazole derivatives and uses thereof | 瑞石生物医药有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-4366733-A1 | TETRAHYDROPYRAZOLOPYRIDINE-ANALOG LIGANDS OF NLRX1 AND USES THEREOF | LANDOS BIOPHARMA, INC. (US) | 2024-05-15 | — | — | EP | disclosed |
| CN-117835980-A | Tetrahydropyrazolopyridine analog ligand of NLRX1 and application thereof | 朗多生物制药股份有限公司 | 2024-04-05 | — | — | CN | disclosed |
| EP-3927427-B1 | LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME | NIMMUNE BIOPHARMA INC (US) | 2024-02-07 | — | — | EP | disclosed |
| US-20230357744-A1 | ENGINEERED TRYPTOPHAN DECARBOXYLASES AND USES THEREOF FOR SYNTHESIZING TRYPTAMINE ANALOGS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2023-11-09 | — | — | US | disclosed |
| EP-4225315-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING INFLAMMATORY OR IMMUNE-MEDIATED CONDITIONS OF SURFACE TISSUES | Nimmune Biopharma, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4214200-A1 | LANCL LIGANDS | Nimmune Biopharma, Inc. (US) | 2023-07-26 | — | — | EP | disclosed |
| CN-113748109-B | Lanthionine C-like protein 2 ligands, cells prepared with said ligands and therapies using said ligands | 朗多生物制药股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| CN-116368133-A | NLRX1 ligand | 朗多生物制药股份有限公司 | 2023-06-30 | — | — | CN | disclosed |
| US-20230192652-A1 | PLXDC2 LIGANDS | LANDOS BIOPHARMA, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| US-6949585-B2 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI CO., LTD. (JP) | 2005-09-27 | — | — | US | disclosed |
| US-20050171132-A1 | Diaminopyrimidine derivatives as selective growth hormone secrectgogue receptor (GHS-R) antagonists | XIN ZHILI (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005030734-A1 | DIAMINOPYRIMIDINE DERIVATIVES AS SELECTIVE GROWTH HORMONE SECRECTGOGUE RECEPTOR (GHS-R) ANTAGONISTS | ABBOTT LABORATORIES (US) | 2005-04-07 | — | — | WO | disclosed |
| US-20050070712-A1 | Pyrimidine derivatives as ghrelin receptor modulators | ABBOTT LABORATORIES | 2005-03-31 | — | — | US | disclosed |
| US-20040082805-A1 | Cyclooctanone derivatives and cyclodecanone derivative, and use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1375465-A9 | CYCLOOCTANONE DERIVATIVE AND CYCLODECANONE DERIVATIVE, AND USE THEREOF | Eisai Co., Ltd. (JP) | 2004-04-14 | — | — | EP | disclosed |
| EP-1375479-A1 | PYRROLIDINE DERIVATIVE AND PROCESS FOR PRODUCING THE SAME | Eisai Co., Ltd. (JP) | 2004-01-02 | — | — | EP | disclosed |
| US-6599917-B1 | A squalene-synthesizing enzyme inhibitor, a cholesterol biosynthesis inhibitor and a triglyceride biosynthesis inhibitor | EISAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| EP-1217001-A1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |